TheraRadar
← Back
Data updated: Nov 8, 2026

Takeda

TAK Big Pharma
ImmunologyMetabolicGastroenterology Execution: Good

Takeda is a major pharmaceutical company focused on Immunology, Metabolic, Gastroenterology. Key products include ENTYVIO.

1945
Since
88
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
34 Small Molecules 21 Biologics

FDA Novel Drug Designations

(2017-2023)
5 Novel 1 First-in-Class 3 Orphan 3 Breakthrough 2 Accelerated 4 Priority Review 2 Fast Track
See 5 novel approvals →
2023 FRUZAQLA (FRUQUINTINIB) Priority Review · Fast Track
2021 LIVTENCITY (MARIBAVIR) First-in-Class · Orphan · Breakthrough · Priority Review
2021 EXKIVITY (MOBOCERTINIB SUCCINATE) Orphan · Breakthrough · Priority Review · Accelerated · Fast Track
2018 MOTEGRITY (PRUCALOPRIDE SUCCINATE)
2017 ALUNBRIG (BRIGATINIB) Orphan · Breakthrough · Priority Review · Accelerated

Takeda at a Glance

  • Leading 6 drug targets across portfolio
  • Fast trial execution (17 months median completion)

Takeda's Recent FDA Approvals

Takeda secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MIMRYLO NDA
2026-08-28
rusfertide acetate
ORZEYFUL NDA
2026-08-05
oveporexton

Takeda's Therapeutic Areas

Takeda's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Metabolic, across 21 biologic and 34 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 31%
3 drugs Phase 3: 49 Phase 2: 22 Phase 1: 24
Metabolic 21%
4 drugs Phase 3: 32 Phase 2: 12 Phase 1: 19
Gastroenterology 19%
4 drugs Phase 3: 29 Phase 2: 9 Phase 1: 20
Oncology 18%
6 drugs Phase 3: 15 Phase 2: 16 Phase 1: 37
Cardiovascular 11%
2 drugs Phase 3: 18 Phase 2: 3 Phase 1: 8

Takeda Pipeline Snapshot

Takeda has 313 active clinical programs from ClinicalTrials.gov — 143 Phase 3, 62 Phase 2 and 108 Phase 1.

143
Phase 3
62
Phase 2
108
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Maribavir
Cytomegalovirus (CMV)
Estimated · aging NCT06439342
Q1 2027
Maribavir
Cytomegalovirus (CMV)
Estimated · stale NCT05319353
Q1 2027
Teduglutide
Short Bowel Syndrome
Estimated · stale NCT06973304
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LIVTENCITY leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Immunology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 154/220 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges